Is there an association between the development of metabolic syndrome in PCOS patients and the C677T MTHFR gene polymorphism?

Pełen tekst

(1)DOI: 10.17772/gp/61751.

(2)

(3)

(4) .

(5)

(6) g i n e kol og i a. Is there an association between the development of metabolic syndrome in PCOS patients and the C677T MTHFR gene polymorphism? Czy istnieje związek między rozwojem zespołu metabolicznego u kobiet z zespołem policystycznych jajników, a polimorfizmem C677T genu reduktazy metylenotetrahydrofolianowej? Katarzyna Ozegowska1, Anna Bogacz2, Joanna Bartkowiak-Wieczorek2, Agnieszka Seremak-Mrozikiewicz3, Leszek Pawelczyk1 1. Department of Infertility and Reproductive Endocrinology, Poznan University of Medical Sciences, Poland Department of Pharmacology and Phytochemistry, Institute of Natural Fibers and Medicinal Plants, Poland Laboratory of Experimental Pharmacogenetics, Department of Clinical Pharmacy and Biopharmacy, Poland 3 Department of Pharmacology and Phytochemistry, Institute of Natural Fibers and Medicinal Plants, Poland Division of Perinatology and Women’s Diseases, Poznan University of Medical Sciences, Poland Laboratory of Molecular Biology, Poznan University of Medical Sciences, Poland 2. Abstract Introduction: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. PCOS is characterized by anovulation, polycystic ovaries, hyperandrogenism leading to infertility, dermatological and psychological problems, as well as the risk of developing Metabolic Syndrome (MetS) and cardiovascular disease (CVD). The exact cause of PCOS remains unclear. Various biochemical and genetic markers have been implicated in predisposition to PCOS, but no single variant has been associated with the syndrome. Some authors connect hyperhomocysteinemia (HHcy) with MetS and its components. The MTHFR gene C677T polymorphism is a common genetic abnormality leading to hyperhomocysteinemia. Objectives: The aim of the study was to confirm the existence of a possible correlation between metabolic disturbances in PCOS and the MTHFR C677T polymorphism. Material and methods: A total of 98 patients diagnosed with PCOS according to the Rotterdam criteria and 101 age-matched healthy controls were included in the study. Genotyping of MTHFR C677T was performed by the real time PCR method.. Corresponding author: Katarzyna Ożegowska Department of Infertility and Reproductive Medicine Poznan University of Medical Sciences Polna 33, 60-535 Poznań, Poland e-mail: k.ozegowska@gmail.com. 246. Otrzymano: 28.12.2015 Zaakceptowano do druku: 10.02.2015. © Polskie Towarzystwo Ginekologiczne. Nr 4/2016.

(7)

(8)

(9)

(10) . DOI: 10.17772/gp/61751. P R A C E. O R Y G I N A L N E g i n e kol og i a. Katarzyna Ozegowska et al. Is there an association between the development of Metabolic Syndrome in PCOS patients and the C677T MTHFR gene polymorphism?. Results: Statistically significant differences were observed between those two groups with regard to body mass index (BMI), waist circumference (WC), hip circumference (HC), fasting insulin, total cholesterol (TC), and triglycerides (TG). No significant differences in the prevalence of the genotypes of the MTHFR C677T gene polymorphism were found between the PCOS group and controls. Despite the lack of significant differences, we observed a tendency for a higher prevalence of the TT genotype in the PCOS group (p=0.06). No statistically significant differences were observed between the PCOS group and the control group in terms of the presence of the MetS components and the predisposition to develop MetS. Conclusions: Our study did not confirm an association between the MTHFR C677T gene polymorphism and the development of MetS in PCOS. Further studies with larger sample size might be useful to determine this association.. Key words: metabolic syndrome / gene polimorphism / polycystic ovary syndrome / / metylenetetrahydrofolate reductase /. Streszczenie Wstęp: Zespól policystycznych jajników ( PCOS) jest najczęstszym zaburzeniem endokrynologicznym u kobiet w wieku rozrodczym, charakteryzującym się brakiem owulacji, jajnikami policystycznymi oraz hiperandrogenizmem, które prowadzą do niepłodności, problemów dermatologicznych i psychologicznych oraz zwiększają ryzyko rozwoju zespołu metabolicznego i choroby sercowo-naczyniowej. Przebadano wiele biochemicznych i genetycznych markerów, które mogłyby mieć wpływ na rozwój PCOS, jednak jak do tej pory nie udało się wskazać jednego pewnego czynnika. Istnieją badania łączące hiperhomocysteinemię z zespołem metabolicznym i jego składowymi. Częstym zaburzeniem genetycznym prowadzącym do hiperhomocysteinemi jest polimorfizm C677T genu reduktazy metylenotetrahydrofolianowej (MTHFR). Cel: Celem badania było zweryfikowanie związku zaburzeń metabolicznych w zespole policystycznych jajników z polimorfizmem genu C677T MTHFR. Materiał i metody: 98 pacjentek ze zdiagnozowanym PCOS na podstawie kryteriów Rotterdamskich zostało porównane ze 101 pacjentkami z grupy kontrolnej dobranej zgodnie wiekowo. Metoda real-time PCR została użyta do wykonania oznaczeń genetycznych. Wyniki: Istotne statystycznie różnice między grupami zauważono w Body Mass Index (BMI), obwodzie talii, obwodzie bioder, poziomie insuliny na czczo, cholesterolu całkowitego, trójglicerydów. Nie zauważono istotnych statystycznie różnic w występowaniu genotypów polimorfizmu C677T genu MTHFR między grupą badaną, a kontrolną. Zaobserwowano jedynie tendencję do częstszego występowania genotypu TT w grupie kobiet z PCOS (p=0,06). Nie zauważono różnic statystycznych między częstością występowania składowych zespołu metabolicznego oraz w rozwoju pełnoobjawowego zespołu metabolicznego między tymi grupami. Wnioski: Nasze badanie nie potwierdziło związku polimorfizmu genu C677T MTHFR z rozwojem zespołu metabolicznego w PCOS. Dalsze badania na większej grupie pacjentek mogłyby być pomocne w ocenie tego związku.. Słowa kluczowe: poliformizm genetyczny / zespól metaboliczny /

(11)

(12)

(13) jajników / redukcja metylenotetrahydrofolianowa /. Introduction

(14) .

(15) !"# .

(16)

(17)

(18) $

(19) $

(20)

(21) $ %

(22) .

(23) &'("# )

(24) . % *

(25) $ . *

(26)

(27) $

(28) !.

(29) $ +*

(30)

(31)

(32)

(33)

(34) .

(35) .+ /04"# ) 5

(36)

(37)

(38)

(39) .

(40) $ $

(41)

(42) 0

(43) $

(44) . $

(45) %

(46)

(47)

(48)

(49)

(50) .

(51)

(52)

(53)

(54)

(55)

(56) $ .

(57)

(58)

(59) .

(60)

(61) $

(62)

(63) . 6'!"# * 7

(64)

(65)

(66) $ $

(67) .

(68) $

(69)

(70) $ . Nr 4/2016. 8

(71)

(72) &"# *

(73) .

(74)

(75)

(76)

(77) % +*

(78) .+

(79) .

(80)

(81)

(82) (/"# )

(83) .

(84) $

(85) .

(86) 7 $

(87)

(88) $ .

(89)

(90) &9: (;: <0!9"#. = =

(91) '

(92)

(93)

(94) .

(95) $ !"# )

(96) .

(97) == *

(98) . $

(99)

(100) $

(101)

(102)

(103).

(104)

(105)

(106) $ !!0!6"# ).

(107)

(108) .

(109)

(110)

(111)

(112) *)=>? '

(113) . @ $

(114) ' '

(115) . &9'&"# ) 7 *)=>?.

(116)

(117)

(118)

(119) +CD

(120) &! &&"

(121) . © Polskie Towarzystwo Ginekologiczne. 247.

(122) P R A C E O R Y G I N A L N E ginekolog i a. DOI: 10.17772/gp/61751.

(123)

(124)

(125) . Katarzyna Ozegowska et al. Is there an association between the development of Metabolic Syndrome in PCOS patients and the C677T MTHFR gene polymorphism?.

(126)

(127)

(128)

(129)

(130)

(131)

(132) . $

(133) %

(134)

(135) 5

(136)

(137) .

(138) 5

(139) E

(140)

(141) . % &('&6"# =

(142)

(143) $ .

(144)

(145)

(146)

(147)

(148)

(149) .

(150)

(151)

(152)

(153) &< &;"# )

(154) $ .

(155)

(156)

(157)

(158) *)=>? <;;) .

(159)

(160) $ $

(161) # ) .

(162)

(163)

(164) $

(165)

(166)

(167)

(168) .

(169) $

(170)

(171) &40(!"#. Objectives )

(172)

(173)

(174)

(175) $

(176) . $

(177) $ $

(178)

(179)

(180) *)=>?. <;;) #. 1. Material and methods 1.1. Study subjects )

(181) +

(182) F .

(183) ? * @

(184) G *

(185) . $ H !9!

(186) +$ !9&# I . <(

(187)

(188) 94

(189) '

(190)

(191) # Inclusion criteria for selection of PCOS cases and controls: )

(192)

(193) 7

(194) . ?

(195)

(196) (&"# D

(197)

(198) $ .

(199)

(200) N .

(201)

(202)

(203)

(204)

(205)

(206)

(207)

(208) .

(209)

(210)

(211)

(212)

(213)

(214) <. 5 #.

(215)

(216) .

(217)

(218) 5 $

(219) $

(220)

(221)

(222) .

(223)

(224) ;' 5 . # =

(225)

(226) 7 $

(227) .

(228) E $

(229) >

(230) 'Q

(231) >Q ((".

(232) R

(233)

(234) R

(235)

(236) #.

(237)

(238)

(239) '

(240) .

(241)

(242)

(243) $

(244) .

(245)

(246) %

(247)

(248) %

(249) .

(250)

(251) .

(252) #. 1.2. Patient evaluation *

(253)

(254)

(255)

(256)

(257)

(258) .

(259)

(260) 5

(261)

(262)

(263) .

(264) $

(265) . I

(266) $

(267)

(268)

(269)

(270) . $

(271)

(272)

(273) 5

(274)

(275)

(276) . I=?

(277) =

(278)

(279) .

(280)

(281) # 8

(282) 5 8*F

(283)

(284)

(285) .

(286) %

(287) $ T

(288) . %R2# D I =

(289)

(290) @

(291)

(292) .

(293) 7

(294) 8*F $ !/#9

(295) !6#6 %R2

(296) . $

(297) 7

(298) 8*F U&9#9 %R2 (/"# D

(299) .

(300)

(301)

(302)

(303) .

(304)

(305)

(306) &0/

(307)

(308)

(309) $

(310) .

(311)

(312) $

(313)

(314) < #. 248. 1.3. Biochemical and hormonal analysis 8

(315)

(316)

(317)

(318)

(319)

(320) . V

(321) $

(322) G =

(323)

(324) 7

(325) .

(326) F 699# 8

(327) $

(328) .

(329)

(330)

(331)

(332)

(333)

(334) $

(335) . $ 4

(336) 9 D*

(337)

(338) !'

(339) #

(340) .

(341)

(342) @

(343)

(344)

(345) .

(346)

(347)

(348)

(349) T

(350) ';9X

(351)

(352) #. ) ;/'

(353)

(354) Q))

(355) .

(356)

(357)

(358)

(359) # 8.

(360) $

(361)

(362) $

(363)

(364)

(365) &9' #

(366) !. # Q $

(367) $

(368) . @

(369) %%

(370) ? +

(371) .

(372) $

(373)

(374)

(375) =

(376) 6!

(377)

(378) @ # F

(379) .

(380) D5Y* F

(381)

(382) . *

(383) Z@ F

(384)

(385) *ZFD D$$# )

(386) =+V

(387) . )Q

(388)

(389)

(390) ? +

(391) .

(392) =+'D =+V'

(393) ) . Q'D

(394) =

(395) 6!

(396)

(397) @

(398) V+V.

(399)

(400)

(401)

(402) [. V+V \

(403) 0 =+V 0 )QR/#. ) 7

(404) [

(405) . /9#90!99#9 RV] =+V &/#90;9#9 R V] /9#90/9#9 RV]

(406) V+V &/#90 &9#9 RV#. 1.4. Molecular analysis Q MTHFR C677T rs49&&

(407) *)=>?. D!64 49&

(408) $

(409) ? . V ^ (49 # +CD

(410)

(411) . $ _FD

(412) 8 * ` _FDQZC. GD# D

(413) . rs49&&

(414) 49& . *)=>?

(415) =$ $ $. ) 8*$

(416) # Q *)=>? .

(417) $

(418)

(419)

(420) # V C

(421) .

(422)

(423)

(424) $ .

(425) 7

(426) #

(427)

(428) V C .

(429) ' ?

(430)

(431)

(432)

(433) N. # ?

(434)

(435)

(436)

(437) .

(438) 6/b /

(439) (9

(440)

(441) /

(442) 6/b.

(443)

(444) / <9b

(445) 5 /

(446) ;!b# Z

(447) 6<'

(448)

(449)

(450) 5

(451)

(452)

(453) +CD.

(454) # )

(455)

(456)

(457)

(458)

(459) V

(460) $

(461) . Z5

(462)

(463)

(464) +

(465)

(466) .

(467)

(468)

(469) 8

(470)

(471) @

(472) G *

(473) .

(474) #. 1.5. Statistical Analysis D

(475)

(476)

(477)

(478)

(479)

(480).

(481) # ) $

(482)

(483) $

(484)

(485) .

(486) 'I %

(487)

(488)

(489) # F

(490)

(491) . *

(492) 'I G

(493) ` %

(494) 'I

(495) . '

(496) $ #

(497)

(498) $

(499) 5

(500) .

(501) T

(502)

(503) F_? !/0;/ .

(504) # 8'

(505) .

(506)

(507) $ *

(508) 'I . G # 'T

(509)

(510)

(511)

(512)

(513) $ .

(514)

(515) *)=>? <;;) . © Polskie Towarzystwo Ginekologiczne. Nr 4/2016.

(516)

(517)

(518)

(519) . P R A C E. DOI: 10.17772/gp/61751. O R Y G I N A L N E g i n e kol og i a. Katarzyna Ozegowska et al. Is there an association between the development of Metabolic Syndrome in PCOS patients and the C677T MTHFR gene polymorphism?. Tab le I . Demographic, anthropometric and biochemical parameters of the studied groups (PCOS cases and controls). Parameter. PCOS. Control. P value. 27.2 ±4.5. 28.1± 3,5. 0.08. 23.7±5.4. 21.7±2,8. 0.00001*. WC (cm). 80.7±12.8. 71.6±12.8. 0.00001*. HC (cm). 101.1±11.3. 97.5±7.4. 0.02*. WHR. 0.79±0.1. 0.73±0.1. 0.06. Fasting glucose (mg/dl). 88.3±9.9. 89.58±9.8. 0.13. Age (yrs) 2. BMI (kg/m ). Fasting insulin (μU/ml). 9.4±7.8. 6.5±3.3. 0.00001*. TC(mg/dl). 189.2±32.5. 169.7±16.0. 0.00005*. TG (mg/dl). 89.8±52.5. 87.9±15.5. 0.00015*. LDL-C (mg/dl). 86.7±13.9. 79.4±9.5. 0.43. HDL-C (mg/dl). 62.4±17.8. 59.2±6.6. 0.44. 3.2±1.1. 3.2±0.8. 0.86. SBP. 114.0±15.0. 112.0±10.2. 0.2. DBP. 70.2±11.1. 71.3±8.9. 0.34. Chol/HDL. A b b re v ia t ions: BMI – body mass index; WC – waist circumference; HC – hip circumference; WHR – waist to hip ratio; TC – total cholesterol; TG – triglycerides; LDL-C – low density lipoprotein cholesterol; HDL-C – high density lipoprotein cholesterol; VAI – visceral adiposity index; SBP – systolic blood pressure; DBP – diastolic blood pressure * P<0,05 was considered statistically significant +Mann Whitney U test was used. $

(520)

(521) $' .

(522)

(523) T # G

(524) .

(525)

(526)

(527)

(528) . *)=>? <;;) # ) ? 6/:. F

(529)

(530)

(531)

(532) % .

(533)

(534) # >

(535)

(536)

(537)

(538) '

(539)

(540) d9#9/

(541) .

(542)

(543)

(544) 7

(545) # V

(546) Z

(547) # I .

(548) $

(549)

(550) $f #. 2. Results 2.1. Demographic and clinical characteristics of study subjects +

(551) $

(552)

(553)

(554)

(555)

(556) .

(557)

(558)

(559)

(560) @ )

(561) $ F# D. $

(562) 7

(563) $ . # 7

(564) $ $ . $

(565) 5 8*F

(566) I . =

(567)

(568) )

(569) . )Q

(570) )Q#. I

(571)

(572)

(573)

(574) $. $

(575)

(576) $ . $

(577)

(578) 7

(579)

(580) . )

(581) $ FF#. 2.2. Genotypic and allelic frequencies Q

(582)

(583) T *)=>? <;;).

(584) )

(585) $ FFF# C 7

(586) .

(587) *)=>? <;;) . $

(588) #. +

(589) % 7

(590) $ . Nr 4/2016.

(591)

(592) )) . \9#9<

(593)

(594) $.

(595)

(596)

(597) $

(598)

(599)

(600)

(601) . $

(602) #. 2.3. Association between C667T gene polymorphism and metabolic syndrome ) &

(603)

(604) . *

(605) F+>

(606) #. C

(607)

(608) 7

(609) $ $ .

(610) . *#. 2.4. Association between the C667T gene polymorphism with individual components of metabolic syndrome )

(611)

(612)

(613) * . *)=>? <;;)

(614)

(615) #. *

(616)

(617)

(618)

(619) 7

(620) .

(621)

(622) $ *)=>? <;;)

(623) .

(624) * )

(625) $ F.# D

(626)

(627) $ . *

(628) *)=>? <;;) . )

(629) $ . $

(630) )) .

(631) )

(632)

(633) $ $ *

(634) . $ #. Discussion D

(635)

(636) $

(637)

(638) T.

(639)

(640) $ .

(641) $

(642)

(643)

(644)

(645) %. © Polskie Towarzystwo Ginekologiczne. 249.

(646) P R A C E O R Y G I N A L N E ginekolog i a.

(647)

(648)

(649) . DOI: 10.17772/gp/61751. Katarzyna Ozegowska et al. Is there an association between the development of Metabolic Syndrome in PCOS patients and the C677T MTHFR gene polymorphism?. Tabl e I I . Patients with metabolic parameters fullfilling IDF MetS criteria. Parameter. IDF criteria. PCOS N=164. Controls N=108. p. 50. 27. <0,09. 42. =0,47. 82. 17. <0,00001. 82. 12. <0,00001. 8. 0. <0,02. 39. 38. =0,4. 15. 11. =0,8. NO. BBP. .

(650). BWC.

(651) . BBBMI. >25 kg/m2. BTG.

(652) . ??HDL-C. <50 mg/dl. BFG.

(653) . 63. A b b re v ia t ions : BMI – body mass index; WC – waist circumference; WHR – waist to hip ratio; TC – total cholesterol; TG – triglycerides; HDL-C – high density lipoprotein cholesterol; BP – blood pressure; * P<0,05 was considered statistically significant Chi2.

(654)

(655)

(656)

(657) #

(658)

(659) . !

(660) $

(661) $ # ) . $

(662)

(663) .

(664)

(665)

(666)

(667)

(668)

(669)

(670) . % $

(671) #. *

(672)

(673)

(674) E . * ("# +

(675)

(676) $ *.

(677)

(678) ==.

(679)

(680) !! !&"# ) % $ . $

(681)

(682)

(683) $

(684)

(685) .

(686)

(687) .

(688)

(689)

(690) +CD

(691) (<0(4"# ) *)=>?. <;;)

(692) $ % $ .

(693) %

(694)

(695) == (6 /9"# ) <;;). *)=>?

(696)

(697)

(698)

(699) . *)=>? @ ==

(700)

(701) .

(702) $

(703)

(704) $ . * &9 && /;"#

(705) #

(706)

(707) .

(708)

(709) $ *)=>?

(710) .

(711) *)=>? .

(712)

(713)

(714) T

(715) .

(716)

(717)

(718) /&"# ) $ % .

(719) $ 7

(720) $

(721) . *)=>? <;;) *

(722) .

(723) #. F 7

(724)

(725) $ .

(726) *)=>? .

(727) # ?

(728) $

(729) .

(730)

(731) )) .

(732) \9#9;# )

(733) $. `

(734)

(735) @

(736) # /("

(737) )

(738)

(739)

(740) # //"# ) *

(741) .

(742) # &/"

(743)

(744) % #&! ). # F %

(745) 7.

(746) 9#;/ ) # F . Y

(747)

(748) # <;;))

(749)

(750)

(751)

(752) 7

(753) . 250.

(754) *

(755) >8Q I#. Q

(756)

(757)

(758) *

(759)

(760) . (</<"# F

(761) $

(762) )).

(763)

(764)

(765)

(766)

(767) %

(768) .

(769)

(770)

(771) # )

(772) .

(773)

(774)

(775) $

(776) $ .

(777)

(778)

(779) 7

(780) %.

(781) .+# D

(782) .

(783) $ *)=>?

(784)

(785)

(786)

(787)

(788) . T

(789) $

(790) . 7

(791)

(792) @

(793)

(794) . %

(795)

(796) )

(797)

(798) 5 .

(799)

(800) # ) <;;)

(801) . % $

(802)

(803) . $ *)=>?

(804) *# )

(805) . $ Y

(806)

(807) # (<"#

(808) . .

(809)

(810) #

(811)

(812) (#9!' % . *

(813)

(814) /;"#. )

(815)

(816) $ *)=>? <;;) .

(817) *

(818)

(819) 7 ` .

(820) # /4"

(821) Z

(822) # /<"# D .

(823)

(824)

(825) 7 .

(826)

(827)

(828) .

(829) $

(830)

(831)

(832)

(833)

(834) .

(835)

(836) 7

(837) 5

(838)

(839) .

(840)

(841) $

(842) 5 . #. )

(843)

(844)

(845) *

(846) . *)=>?

(847)

(848) 7

(849) .

(850)

(851) *#.

(852) 7 Y

(853)

(854) # (<" 5 $ .

(855) 7

(856)

(857)

(858) ))

(859) . $ >8Q

(860) . /; /6"# )

(861)

(862) . © Polskie Towarzystwo Ginekologiczne. Nr 4/2016.

(863)

(864)

(865)

(866) . P R A C E. DOI: 10.17772/gp/61751. O R Y G I N A L N E g i n e kol og i a. Katarzyna Ozegowska et al. Is there an association between the development of Metabolic Syndrome in PCOS patients and the C677T MTHFR gene polymorphism?. Tab le I I I . Genotype distribution and allele frequency of MTHFR C677T polymorphism in the studied population ( PCOS women and Control Group). PCOS (N=164) (%)*. Control (N=108) (%). OR (95% CI). P value. CC. 87 (51.8). 53(53.5). 0.93 (0.5668 - 1.5332). 0.7822. CT. 52 (30,9). 37(37.4). 0.75 (0.4456-1.2664). 0.2829. TT. 29 (17.3). 9 (9.1). 2.09 (0.9436- 4.6131). 0.0693. C. 226 (67.3). 143 (72.2). 0.93 (0.7086-1.2240). 0.6099. T. 110 (32.7). 55(27.8). 1.18 (0.8155-1.7033). 0.3818. Polymorphism. * Values are given as number (%). Ta b le I V. Association of MTHFR C677T gene polymorphism with single component of MetS. Genetic Model. High WC*. High BP. High FBG. High TG. Low HDL-C. Homozygous codominant (TT/CC). 1.0 (0.15-6.53). 0.33 (0.02-7.14). 0.8 (0.04-17.2). 1.0 (0.01-255.6). 9.5 (0.83-109.2). Heterozygous codominant (CT/CC). 1.67 (0.29-9.45). 0.04 (0.01-0.62). 0.4 (0.05-3.42). 3.0 (0.09-473.1). 1.22 (0.31-4.84). Dominant (TT+CT/CC). 1.33 (0.32-5.64). 0.09 (0.01-1.00). 0.5 (0.07-3.35). 3.0 (0.09-473.1). 1.81 ( 0.51-6.4). Recessive (TT/ CT+CC). 0.85 (0.14-5.07). 1.64 (0.14-19.4). 1.14 (0.06-21.9). 0.33 (0.01-52.6). 8.73 (0.82-92.9). Allelic (T/C). 1.11 (0.38-3.25). 0.4 (0.11-1.51). 0.67 (0.15-2.98). 1.0 (0.01-92.4). 2.20 (0.85-5.70). A b b re v ia t io ns : MTHFR – methylenetetrahydrofolate reductase; MTRR – methionine synthase reductase; OR – odds ratio; CI – confidence interval; BP – blood pressure; FBG – fasting blood pressure; TG – triglycerides; HDL-C – high density lipoprotein cholesterol; WC – waist circumference. Chi2 test was used.. Tab le . V. MTHFR C677T polymorphisms and the number of MetS components. Genetic Model. 1 Components.

(867). Homozygous codominant (TT/CC). 0.7 ( 0.1-4.2). 1.3 (0.5-3.3). Heterozygous codominant (CT/CC). 1.2 (0.4-3.5). 0.7 ( 0.4-1.4). Dominant (TT+CT / CC). 1.1 (0.4-3.0). 0.8 ( 0.5-1.5). Recessive (TT/ CT+CC). 0.6 (0.1-3.6). 1.5 ( 0.6-3.6). Allelic (T/C). 0.9 (0.4-2.1). 0.9 ( 0.6-1.3). Chi2 test was used..

(868)

(869) $ .

(870)

(871)

(872)

(873) 7

(874)

(875) .

(876)

(877)

(878)

(879) $#.

(880) Y

(881)

(882) # (<"

(883) .

(884) .

(885) # /;"

(886) $ I

(887) . *)=>? <;;) #

(888) . ) @@

(889) # <9"# F

(890)

(891) E .

(892)

(893) @

(894) #. ) H

(895)

(896) # &/"

(897)

(898)

(899) . %

(900)

(901) ) . *)=>? <;;) $

(902) $

(903) . Nr 4/2016. . D+

(904) #

(905) .

(906)

(907)

(908)

(909) )

(910) . )Q

(911)

(912)

(913) $

(914) .

(915)

(916) %

(917)

(918) #. C

(919)

(920)

(921)

(922) $ .

(923) $ * #. * '

(924) '

(925)

(926) .

(927) $

(928)

(929) . %

(930) $ *)=>? <;;)

(931) .

(932)

(933)

(934)

(935) $

(936) 7 . #. © Polskie Towarzystwo Ginekologiczne. 251.

(937) P R A C E O R Y G I N A L N E ginekolog i a. DOI: 10.17772/gp/61751.

(938)

(939)

(940) . Katarzyna Ozegowska et al. Is there an association between the development of Metabolic Syndrome in PCOS patients and the C677T MTHFR gene polymorphism?.

(941)

(942)

(943)

(944)

(945) .